Article Text

Download PDFPDF
A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats
  1. A Bhatwadekar1,
  2. J V Glenn1,
  3. J L Figarola2,
  4. S Scott2,
  5. T A Gardiner1,
  6. S Rahbar2,
  7. A W Stitt1
  1. 1
    Centre for Vision Science, Queen’s University Belfast, Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland
  2. 2
    Department of Diabetes and Endocrinology, Gonda Building, City of Hope National Medical Centre, Duarte, CA 91010, USA
  1. Professor A W Stitt, Centre for Vision Science, Queen’s University Belfast, Royal Victoria Hospital, Grosvenor Road Belfast BT 126BA, Northern Ireland, UK; a.stitt{at}


Background: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties.

Aim: To explore the role of LR-90 in the progression of experimental diabetic retinopathy.

Methods: Streptozotocin-induced diabetic Sprague–Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy.

Results: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001).

Conclusion: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: City of Hope National Medical Centre is applying for a patent for this molecule.